Alkermes plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALKS research report →
About the company
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
- CEO
- Richard F. Pops
- IPO
- 1991
- Employees
- 2,095
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $9.10B
- P/E
- 58.69
- P/S
- 5.82
- P/B
- 5.18
- EV/EBITDA
- 37.37
- Div Yield
- 0.00%
- Gross Margin
- 86.63%
- Op Margin
- 12.28%
- Net Margin
- 9.78%
- ROE
- 8.82%
- ROIC
- 3.89%
- Revenue
- $1.48B · -5.25%
- Net Income
- $241.66M · -34.16%
- EPS
- $1.47 · -33.78%
- Op Income
- $253.96M
- FCF YoY
- 18.41%
- 52W High
- $55.28
- 52W Low
- $25.17
- 50D MA
- $41.01
- 200D MA
- $33.23
- Beta
- 0.29
- Avg Volume
- 2.28M
Get TickerSpark's AI analysis on ALKS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Hopkinson Craig C. | other | 5,000 |
| Jul 1, 26 | Hopkinson Craig C. | sell | 8,300 |
| Jul 1, 26 | Hopkinson Craig C. | sell | 700 |
| Jul 1, 26 | Hopkinson Craig C. | other | 5,000 |
| Jun 12, 26 | Wright Christopher I | sell | 2,000 |
| Jun 4, 26 | Gaffin David Joseph | sell | 2,034 |
| Jun 1, 26 | Hopkinson Craig C. | other | 5,000 |
| Jun 1, 26 | Hopkinson Craig C. | sell | 9,000 |
| Jun 1, 26 | Hopkinson Craig C. | other | 5,000 |
| May 29, 26 | Parisi Samuel Joseph | other | 12,825 |
Our ALKS coverage
Recent articles, reports, and earnings notes.
No research on ALKS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALKS report →Similar companies
Peers in the same neighborhood.